NLS Pharmaceutics AG and Kadimastem Ltd. have announced that the U.S. Securities and Exchange Commission has declared effective their registration statement on Form F-4 related to their proposed merger. This marks the final regulatory step needed for closing the merger. Upon completion, the combined company will be known as NewCelX Ltd. and will continue to be publicly traded on Nasdaq under the ticker "NCEL." The merger will unite Kadimastem's cell therapy platforms with NLS's expertise in small-molecule therapies, creating a diversified pipeline targeting CNS disorders and metabolic diseases.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-086348), on September 10, 2025, and is solely responsible for the information contained therein.